Oxford BioTherapeutics
Oxton
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $33.2M
- Last round: Series Unknown (Jan 2021)
- Website: oxfordbiotherapeutics.com
- Phone: 44 1235 861 770
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/oxford-biotherapeutics-8793 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.